Sarah Devine, MD
Internal Medicine · Harlan, IANPI 1639286016
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 227 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$397
- Novo Nordisk$377
- Lilly USA, LLC$370
- Novartis$334
- Bayer$323
- AstraZeneca$301
- plus $2K from 34 others
What the payments were for
- Consulting fees$160%
- Food & beverage$3,724100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,740 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 208 | $132,959 |
| OzempicSemaglutide | 116 | $128,017 |
| XifaxanRifaximin | 11 | $33,787 |
| MounjaroTirzepatide | 22 | $31,221 |
| XareltoRivaroxaban | 64 | $28,868 |
| FarxigaDapagliflozin Propanediol | 20 | $20,932 |
| JanuviaSitagliptin Phosphate | 51 | $20,310 |
| EntrestoSacubitril/Valsartan | 15 | $19,414 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $17,953 |
| LinzessLinaclotide | 16 | $15,423 |
| JardianceEmpagliflozin | 23 | $14,070 |
| MyrbetriqMirabegron | 43 | $11,637 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,564 |
| PrevacidLansoprazole | 12 | $7,558 |
| Colesevelam Hcl | 42 | $6,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $175 | $132,959208 claims |
| Novo NordiskOzempic | $377 | $128,017116 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $133 | $33,78711 claims |
| Lilly USA, LLCMounjaro | $370 | $31,22122 claims |
| Johnson & JohnsonXarelto | $190 | $28,86864 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $42 | $26,51747 claims |
| AstraZenecaFarxiga, Symbicort | $301 | $25,68040 claims |
| MerckJanuvia | $69 | $20,31051 claims |
| NovartisEntresto | $334 | $19,41415 claims |
| Boehringer IngelheimJardiance, Pradaxa | $77 | $16,49735 claims |
| AbbVieLinzess | $41 | $15,42316 claims |
| Astellas Pharma US IncMyrbetriq | $68 | $11,63743 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Harlan
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Alan KricsfeldCouncil Bluffs$49K
- Aziz HammoudIowa City$29K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Isam MararCouncil Bluffs$23K
- Ali SaeedCedar Rapids$17K
- Lazaro RabangUrbandale$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.